Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $15.00.

A number of brokerages recently issued reports on FOLD. SVB Leerink lowered their price target on shares of Amicus Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Thursday, February 24th. StockNews.com assumed coverage on shares of Amicus Therapeutics in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, The Goldman Sachs Group started coverage on Amicus Therapeutics in a report on Wednesday, April 13th. They issued a “neutral” rating for the company.

In other news, COO Bradley L. Campbell sold 16,410 shares of Amicus Therapeutics stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $10.00, for a total transaction of $164,100.00. Following the completion of the sale, the chief operating officer now directly owns 689,618 shares of the company’s stock, valued at approximately $6,896,180. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Daphne Quimi sold 4,396 shares of the business’s stock in a transaction on Friday, June 17th. The stock was sold at an average price of $9.00, for a total transaction of $39,564.00. Following the transaction, the chief financial officer now owns 345,507 shares of the company’s stock, valued at approximately $3,109,563. The disclosure for this sale can be found here. Over the last quarter, insiders sold 103,788 shares of company stock worth $886,486. Insiders own 2.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in FOLD. Dark Forest Capital Management LP raised its position in shares of Amicus Therapeutics by 1,967.5% during the 3rd quarter. Dark Forest Capital Management LP now owns 4,838 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 4,604 shares in the last quarter. Invesco Ltd. lifted its position in shares of Amicus Therapeutics by 13.7% during the 3rd quarter. Invesco Ltd. now owns 169,533 shares of the biopharmaceutical company’s stock worth $1,619,000 after buying an additional 20,439 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Amicus Therapeutics by 8.0% in the 3rd quarter. Royal Bank of Canada now owns 158,227 shares of the biopharmaceutical company’s stock valued at $1,512,000 after buying an additional 11,657 shares in the last quarter. Gotham Asset Management LLC purchased a new position in shares of Amicus Therapeutics in the 3rd quarter valued at $161,000. Finally, Tudor Investment Corp Et Al acquired a new stake in Amicus Therapeutics during the 3rd quarter worth $120,000.

FOLD opened at $9.98 on Friday. The company has a current ratio of 4.00, a quick ratio of 3.81 and a debt-to-equity ratio of 1.63. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -10.29 and a beta of 1.41. Amicus Therapeutics has a 12 month low of $5.91 and a 12 month high of $12.63. The stock has a fifty day moving average price of $7.81 and a 200-day moving average price of $9.07.

Amicus Therapeutics (NASDAQ:FOLD – Get Rating) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). The business had revenue of $78.72 million for the quarter, compared to analysts’ expectations of $76.97 million. Amicus Therapeutics had a negative return on equity of 95.05% and a negative net margin of 84.97%. During the same quarter in the previous year, the firm posted ($0.25) EPS. On average, equities research analysts forecast that Amicus Therapeutics will post -0.89 EPS for the current year.

Amicus Therapeutics Company Profile (Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

Featured Stories